Intuitive Surgical (NASDAQ:ISRG) doesn't have any direct connection to COVID-19, but many see the robotic surgery leader as a vital piece of ensuring that medical professionals can safely conduct procedures with minimal risk to themselves and their patients, and its stock climbed considerably.As CEO Alex Gorsky explained in the conference call after J&J's earnings Thursday morning, it could be late 2022 before trials begin, with the approval process necessarily taking longer still.